TY - JOUR T1 - Comparative evaluation of castrate resistant metastatic Prostate Cancer with 68 Ga DOTA RGD PET/CT and 68 Ga PSMA: Pilot study JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1345 LP - 1345 VL - 62 IS - supplement 1 AU - Francisco Osvaldo Garcia-Perez AU - Davanzo Lopez Jenny Y1 - 2021/05/01 UR - http://jnm.snmjournals.org/content/62/supplement_1/1345.abstract N2 - 1345Introduction: Integrin αvβ3 is highly expressed in prostate cancer (PCa), is part of hallmark in cancer and key factor in tumor invasion, angiogenesis and metastasis formation. Therefore, the αv β3 integrin is considered a very promising target for imaging the expression of integrins in (CaP). This study evaluated the potential of the new integrin-related agent αvβ3 68Ga DOTA-RGD compared to 68Ga PSMA to assess metastatic PCa by positron emission tomography. Objectives: To evaluate the potential of the cyclic peptide RGD with 68Ga for the detection of bone and visceral metastatic tumor disease in patients with prostate cancer and compare uptake parameters with different radio-tracers. Methods: 10 patients with metastatic prostate cancer were retrospectively evaluated by PET / CT studies with 68Ga DOTA RGD and 68Ga PSMA in a period of no more than 7 days between both studies in the department of nuclear medicine and molecular imaging of the National Cancer Institute between the months of August to November 2017. Results: The median age was 65 years ( +/- 8.5 y/o ) with a mean Gleason score of 8 (range 7-9) and a mean prostate specific antigen (PSA) level of 65.8 (range 30-845ng/ml). A total of 70 detectable lesions were detected by both methods. 3 patients showed superscan and the semi-quantitative analysis was done using 11 body regions taking into account the sites of greatest uptake. 68Ga DOTA-RGD maximum standardized uptake value (SUVmax) in bone metastases (number of lesions = 40) was 4.0 (range 2-6.9), in lymph node metastases (number of lesions: 19) SUVmax 2.0 (range 1-5.8) and in lesions primary in the prostate (n = 9) 4.6 (range 3-7.3). In the background tissue, SUVmax in blood was 1.5 ± 0.3 and in muscle 0.8 ± 0.1. SUVmax values of 68Ga PSMA-11 for tumors were in bone metastases (number of lesions = 40) of 6.8 (1.8-19.9), in lymph node metastases (number of lesions: 19) SUVmax 4.9 (1- 6.7) and in primary lesions in the prostate (n = 9) SUVmax 8.8 (range 4.6-14.1). there were 5 discordant lesions in which the RGD had higher uptake. Conclusions: RGD can be used as imaging agent for clinical use when evaluating the expression of integrin αv β3 in patients with metastatic prostate cancer, especially with bone involvement and have a potential rol in teragnostics in complement with PSMA. ER -